Biotica regains worldwide rights to its rapamycin analogue program

Biotica Technology Ltd. (Cambridge, UK) today announced that it has regained full rights from Pfizer Inc. (NYSE: PFE) to its rapamycin analogue program, including transfer of data and materials. Biotica’s rapamycin analogue program, partnered in 2006 with Wyeth Pharmaceuticals (acquired by Pfizer in October 2009), includes clinical candidates for the treatment of neuro-inflammatory and other diseases. “Our compounds are supported by a strong data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need,” commented Dr. Edward Hodgkin, Chief Executive Officer of Biotica. Since the original Research and License Agreement in 2006, Pfizer has explored the potential of these compounds in several diseases, and in particular has extensively profiled candidate drugs in multiple sclerosis and systemic lupus erythematosus. Biotica intends to continue development in these indications. “Pfizer enjoyed a productive collaboration with Biotica,” said Dr. Mary Collins, Chief Scientific Officer, Immunology and Autoimmunity Research Unit, Pfizer. “The decision to return this program to Biotica was made as part of Pfizer’s portfolio review process. We wish Biotica success as it moves its analogue program forward.” Having consolidated its leading position in polyketide engineering after acquisition of IP from BristolMyers Squibb in 2009, Biotica is advancing a strong pipeline of engineered polyketides including its bestin-class anti-viral cyclophilin inhibitors and the rapamycin analogue program. -ENDS- For further information contact: Dr Edward Hodgkin CEO, Biotica Tel: +44 (0)1799 532920 Nicole Yost / Dimithri Wignarajah College Hill Life Sciences Tel: +44 (0)20 7 457 2020 mailto: [email protected] @collegehill.com About Biotica Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programmes supported by clinical validation. These include nPT-mTOR (unique mTOR inhibitors partnered with Pfizer), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogues partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit w ww.biotica.com. Share Sign up for the latest Pfizer Wire news alerts Receive real-time updates on Pfizer’s news delivered directly to your inbox. Our Pipeline: Potential Breakthroughs in the Making We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline. Corporate Fact Sheet For more than 170 years, Pfizer has worked to make a difference for all who rely on us. Executive Leadership Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company. Sign up for the latest Pfizer Wire news alerts Receive real-time updates on Pfizer’s news delivered directly to your inbox. Our Pipeline: Potential Breakthroughs in the Making We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline. Corporate Fact Sheet For more than 170 years, Pfizer has worked to make a difference for all who rely on us. Executive Leadership Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company. Button previous Button next Pfizer wire Stay up to date on the latest news and alerts through the Pfizer Wire Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. Sign Up Now Details Investors Media Careers Partners PfizerForAll Healthcare Professionals Grant Seekers Supplier & B2B Resources Privacy Statement Accessibility Statement Terms of Use Contact Us Close Glossary © 2026 Pfizer Inc. All rights reserved This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. Twitter Facebook Linked In Instagram Youtube

The release as fetched from its publisher. pfizer.com ↗